Apellis receives negative trend vote on EU MAA for pegcetacoplan; expects CHMP negative opinion in Jan 2024

Apellis Pharmaceuticals, Inc.

CHMP negative trend vote on MAA for intravitreal pegcetacoplan for geographic atrophy (GA) after Dec 13 oral explanation.
Apellis expects CHMP to adopt negative opinion at Jan 22-25, 2024 meeting.
Company plans to appeal and seek re-examination of the opinion.
Pegcetacoplan is for GA secondary to age-related macular degeneration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.